Directorio

We are doing this study to learn if SAPIEN 3 valve system is safe and will work with adults and children who have a dysfunctional right ventricular outflow tract (RVOT) conduit or have an implanted valve in the pulmonic position.

The study wants to learn three things: 1. How many patients with medulloblastoma can live at least 4 months without their tumor getting worse. 2. How many patients with DIPG live for 1 year after getting radiation and the PEP-CMV vaccine. 3. How many patients with HGG live for 1 year without their tumor getting worse after radiation and the PEP-CMV vaccine.

People in this study will visit the research center two times each month to see the study doctor. The study can last up to 2 years. Treatment happens in cycles, and each cycle is 28 days long, which is about 4 weeks. A person can have up to 26 cycles, which equals about 2 years of treatment. The amount of medicine given will depend on the person’s weight, which is checked before each new cycle. The medicine is called tocilizumab. It blocks a protein called interleukin-6, which causes swelling in the body. This medicine is usually used for diseases where the immune system attacks the body, like arthritis, and it can also help with a problem called cytokine release syndrome after certain cancer treatments.

We are doing this study to learn how to best support young women making decisions about breast cancer surgery. We want to know what makes women feel uncertain about their decision-making so we can become better at providing the information they need. This study involves testing a web-based decision support tool that is designed to help young women with newly diagnosed breast cancer with their surgical decisions.

People in the study will get a special medicine called CTIM-76 through a tube in their arm once a week. Each round of treatment lasts 4 weeks. They can keep getting the medicine as long as it helps and doesn’t cause too many problems. Doctors will check on them often with visits, blood tests, and scans to see if the medicine is working and if it’s safe. Some people will start with small doses, and the amount may go up as doctors learn more.

We are doing this study to find out if an experimental drug called Actinium-225 rosopatamab tetraxetan (the study drug) is a safe and effective option for patients with castration-resistant prostate cancer (CRPC).

The goal of this study is to find out if shots of a medicine called omalizumab, also known as Xolair, can lower the number of times people have bad flare-ups of their illness each year.

People who join this study will answer surveys by phone, online, or in person. They will also give regular blood samples. Some people will be asked to do extra tests that check how their body handles sugar, measure special biomarkers, and look at how well their blood vessels work. Participants will be followed for two years. The study will also use information from their electronic health records over time.